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Studies in simplemodel organisms have yielded crucial insights into the genetic andmolec-
ular aspects of longevity. FOXO,which ismost notable for its associationwith longevity, and
its upstream regulators such as sirtuins have received particular attention in translational
research because these genes modulate cell survival in several models of neurodegener-
ative diseases.There is a large amount of knowledge on the pathways that regulate FOXO
activity and genes that may be regulated by FOXO. However, for the same reason that the
FOXO network is a complex stress response system, its therapeutic potential to develop
disease-modifying strategies requires further examination. Although the FOXO network
contains druggable genes such as sirtuins and AMPK, whether they should be activated or
inhibited and whether protection against the early or late phases of neuronal cell decline
might require opposite therapeutic strategies remains unclear. Additionally, the mode of
action of small compound molecules believed to act on FOXO network targets was ques-
tioned.This review recapitulates essential facts and questions about the promises of FOXO
and its interactors in neurodegenerative disease.
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INTRODUCTION
Amajor challenge in neurodegenerative disease research is to iden-
tify disease-modifying strategies. Given the complexity of sporadic
disease such as Alzheimer’s disease (AD) or Parkinson’s disease
(PD), the study of inherited neurodegenerative disease is expected
to shed light on the mechanisms that underlie neurodegeneration.
In this respect, Huntington’s disease (HD), a dominantly inher-
ited disease with CAG expansion in the huntingtin (htt) gene and
expanded polyglutamine (polyQ) tracts in the htt protein caus-
ing striatal and cortical degeneration (Walker, 2007) has become
a “model neurodegenerative disease.” The large number of mod-
els for HD, the knowledge on HD mechanisms (Zuccato et al.,
2010) and the availability of well-characterized cohorts of HD
subjects indeed provide a unique framework in which to inves-
tigate the therapeutic potential of target genes and pathways.
Among the many genes that could be targeted in HD (Zuccato
et al., 2010), longevity modulators, and more largely, genes which
are essential to cellular homeostasis are the subject of intense
research because they may directly regulate important cell sur-
vival mechanisms such as for example oxidative stress response
and protein quality control. While several genes may modulate
lifespan (Narasimhan et al., 2009), a limited number of genes
may function to promote longevity. This is notably true for the
FOXO proteins, a family of forkhead transcription factors that is
conserved from Caenorhabditis Elegans (C. elegans) to mammals.
FOXO factors indeed increase longevity in invertebrates, and in
mammals they have a wide range of functions as further detailed
below. The purpose of this review is to discuss the role of FOXO
proteins andmembers of the FOXOnetwork as neurodegeneration
modulators.
THE FOXO NETWORK
Several signaling pathways such as the PI3K–AKT pathway, stress-
activated pathways such as the MST-1 and JNK pathways, and
the SIR-2 and AMPK pathways converge onto FOXO proteins
to regulate a variety of biological processes which are important
to development, metabolism, tumor suppression, and longevity
(Calnan and Brunet, 2008). A large number of studies have indi-
cated that, in response to external stimuli including growth factors
such as insulin and insulin-like growth factor (IGF-1), nutri-
ents, cytokines, and oxidative stress stimuli, these pathways are
able to regulate the subcellular localization, DNA binding activ-
ity, transcriptional activity, and stability of these FOXO proteins.
These studies have been thoroughly reviewed in excellent arti-
cles to which to refer for more details (Greer and Brunet, 2005;
Calnan and Brunet, 2008; Landis and Murphy, 2010; Yen et al.,
2011); a ﬁnely tuned regulatory network is emphasized in which,
through a series of context-dependent post-translational modi-
ﬁcations and interactions with co-regulators, FOXO proteins are
able to integrate several types of external stimuli to regulate gene
expression and modulate cell cycle arrest, apoptosis, autophagy,
angiogenesis, differentiation, stress resistance, stem cell mainte-
nance, glucogenesis, and food intake. Nutrient-sensing pathways
are important upstream components of this regulatory network.
Nutrient-sensing factors such as insulin/insulin-like growth fac-
tor (IGF) signaling (IIS), NAD+-dependent histone deacetylases
(sirtuins/SIR-2/SIRTs), the target of rapamycin (TOR) kinase, and
ribosomal S6 Kinase (TOR/S6K) pathway and the AMPK path-
way may be targeted by dietary restriction to slow aging (Cabreiro
and Gems, 2010; Chiacchiera and Simone, 2010). Additionally,
nutrient-sensingpathways are also key regulators of FOXOactivity.
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It is for example well-established that IIS modiﬁes FOXO proteins
at speciﬁc phosphorylation sites, with reduction of IIS activating
FOXO,whichmay translate into lifespan extension in invertebrates
(Calnan and Brunet, 2008). Besides IIS and modulation of FOXO
phosphorylation, the SIRT1 nutrient-sensing pathway and modu-
lation of FOXO acetylation is another important FOXO regulator.
Increased sir-2.1/SIRT1 dosage in high-copy sir-2.1 transgene con-
taining strains was indeed found to strongly increase lifespan
in C. elegans, an effect that requires daf-16 /FOXO (Tissenbaum
and Guarente, 2001), suggesting that sirtuins could play impor-
tant roles in lifespan extension. This notion has been recently
challenged by additional studies in C. elegans and Drosophila
melanogaster (Burnett et al., 2011; Rizki et al., 2011). These stud-
ies revealed that lifespan extension may be partially attributable to
background mutations producing a dye-ﬁlling defective (“Dyf”)
phenotype in high-copy sir-2.1 overexpressor strains (Burnett
et al., 2011; Rizki et al., 2011). While this raised the possibility
that sirtuins might not be longevity-promoting factors to that
extent, two independent studies indicated that lifespan extension
(10–15%) may also be achieved in low-copy sir-2.1 overexpres-
sor strains (Rizki et al., 2011; Viswanathan and Guarente, 2011).
Importantly, one of theses studies (Rizki et al., 2011) was con-
sistent with the notion that sir-2.1 interacts with daf-16 /FOXO
and its co-factors such as 14-3-3 proteins in modulating lifes-
pan (Berdichevsky et al., 2006). Furthermore, background muta-
tions were not responsible for the strong level of neuroprotection
achieved againstmutant polyQs by sir-2.1 overexpression (Burnett
et al., 2011). Thus, while additional investigation will be needed to
determine to which extent sirtuins may promote lifespan exten-
sion, sirtuins stand as important longevity factors that are relevant
to neuronal protection in neurodegenerative disease and other
protective effects in metabolic disease (Kim et al., 2007; Baur et al.,
2010; Burgess, 2011; Jeong et al., 2011; Jiang et al., 2011). One may
wonder why mutations producing a Dyf phenotype were found
in sir-2.1 overexpressor strains despite the care made by the C.
elegans community with distributing mutants after multiple out-
crosses. The answermight come from studiesmadewith the search
for mutants resistant to avermectin (Rand and Johnson, 1995),
an antiparasitic drug. Many low-level ivermectin resistance muta-
tions in che, osm, and dyf genes may produce defects in the amphid
sensilla, low-level ivermectin resistance is common in C. elegans
(1 in 5000 eggs in the absence of mutagenesis) and the ivermectin
resistance allele frequency inwild nematode populationsmay be as
high as 1% (C. D. Johnson, personal communication). Addition-
ally, mutations that cause defects in sensory cilia genes may also
extend longevity (Apfeld and Kenyon, 1999). The dyf mutations
may thus occur at relatively high rates, which calls for the regular
assessment of C. elegans mutants for dye-ﬁlling defects in studies
of longevity.
In addition to be regulated by kinases and deacetylases, FOXO
activity is regulated by ubiquitin complex members such as Skp2,
a protein that promotes FOXO1 degradation (Huang et al., 2005),
and by co-factors such as β-catenin, a protein that binds to
FOXO3a and regulates its transcriptional activity in response to
oxidative stress (Essers et al., 2005). The FOXO proteins may com-
petewith the canonicalWnt effectorT cell factor (TCF) for binding
to β-catenin (Hoogeboom et al., 2008), which further highlighted
the importance of β-catenin in the regulation of FOXO activity.
While FOXO proteins may act together with other transcription
factors to regulate gene expression (Landis and Murphy, 2010),
they stand at the center of a large network of upstream regulators,
co-factors, and downstream targets (Figure 1) which are impor-
tant for cell homeostasis. Interestingly, studies based on chromatin
immunoprecipitation (Oh et al., 2006; Schuster et al., 2010), gene
expression proﬁling in C. elegans (McElwee et al., 2003; Murphy
et al., 2003) and mouse neural stem cells (NSCs; Paik et al., 2009;
Renault et al., 2009), and other approaches (Lee et al., 2003; Yu
et al., 2008) highlighted thousands of putative FOXO-regulated
genes (Jensen et al., 2006; Murphy, 2006). These results open the
avenue to a better understanding of FOXO activity in regulating
downstream mechanisms in speciﬁc contexts. Given that FOXO
proteins act in speciﬁc cells and tissues to execute different outputs
(Landis and Murphy, 2010), it is anticipated that speciﬁc tran-
scriptional targets may be engaged into different FOXO-mediated
responses. Gene expression studies performed in either C. elegans
nematodes (McElwee et al., 2003; Murphy et al., 2003) or mouse
NSCs (Lee et al., 2003; Yu et al., 2008) emphasized a small number
of FOXO-regulated genes across species and biological conditions
(Table 1). Although poor overlap may be partially attributable to
differences in the species and/or methods used for gene expression
proﬁling, these studies suggest that FOXOproteins indeed regulate
speciﬁc targets in different contexts. In addition to being impor-
tant for stem cell homeostasis and adult longevity, FOXO factors
are involved in development and cell differentiation (Kitamura
et al., 2007; Demontis and Perrimon, 2009; Yuan et al., 2009; de la
Torre-Ubieta et al., 2010; Kerdiles et al., 2010; Schuff et al., 2010),
and they may be important to promote adult neurogenesis as sug-
gested by studies in Drosophila melanogaster (Siegrist et al., 2010).
Thus, FOXO factors may be essential to cell response homeostasis
during the entire lifetime of a living organism. As such, it is not
surprising that FOXO proteins and their main regulators such as
sirtuins were implicated in the protection against age-associated
diseases such as cancer, diabetes, cardiovascular disease, and neu-
rodegeneration (Dansen and Burgering, 2008; Chiacchiera and
Simone, 2010; Herranz and Serrano, 2010).
THE SIR-2/FOXO PATHWAY AND ITS ROLE IN DEGENERATIVE
DISEASE
For the same reason that pathways converging onto FOXO are
important to cell survival and longevity, they are of particular
interest to explore how to promote neuron or muscle cell sur-
vival in degenerative disease. Over the past years, accumulating
evidence on the therapeutic potential of FOXO and its interac-
tors for age-related diseases has been obtained. Perhaps the ﬁrst
observation suggesting that longevity-promoting factors might be
able to modulate the toxicity of degenerative disease proteins was
obtained in the nematode C. elegans. In transgenic nematodes
expressing polyQ tracts in body wall muscle cells, reducing IIS
by use of age-1/PI3K loss-of-function (LOF) mutants decreased
the toxicity associated to expanded polyQs, and this effect was
dependent on daf-16 /FOXO (Morley et al., 2002). Direct evi-
dence for longevity-promoting factors such as SIR-2 and FOXO
to protect diseased neurons at an early stage of cellular decline
was obtained by using a C. elegans model of HD pathogenesis
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Table 1 | Putative FOXO targets emphasized by microarray analysis in either C. elegans or mouse NSCs, or both.
Mouse gene name Worm ORF ID C. elegans Mouse NSCs
Murphy et al.
(2003)
McElwee et al.
(2003)*
Renault et al.
(2009)
Paik et al.
(2009)
Cav1 T13F2.8 U – D –
Mxd1 R03E9.1 D – D D
Sod2 C08A9.1 D U – –
Crisp F49E11.9, H10D18.2, ZK384.1, ZK384.2 D U (F49E11.9) – –
RIKEN cDNA 6230409E13 C54D10.1 D U – –
Nxnl2 F17B5.1 D U – –
Dgat2 K07B1.4 D U – –
Birc5 C50B8.2 – U – U
Myo1b F29D10.4 – U – U
Slc25a5 W02D3.6 – U – U
B3galt1 E03H4.11 U – – U
Chrna7 R02E12.8 U – – U
Gmeb1 C44F1.2 U – – U
Gspt1 H19N07.1 U – – U
Jag1 R107.8 U – – U
Lta4h ZC416.6 U – – U
Mapk8 B0478.1 U – – U
Pcna W03D2.4 U – – U
Psmc5 Y49E10.1 U – – U
Bphl K01A2.5 U – – D
Dpyd C25F6.3 U – – D
Slc15a2 K04E7.2 U – – D
Comtd1 Y40B10A.2, Y40B10A.6 D – – U
Gnb5 F52A8.2 D – – U
Icmt F21F3.3 D – – U
Rexo1 Y56A3A.33 D – – U
Abhd4 C37H5.2 D – – D
Acsl3 C46F4.2 D – – D
Alkbh4 F09F7.7 D – – D
Cat Y54G11A.6 D – – D
Cyb5 W02D3.1 D – – D
Fads2 W08D2.4 D – – D
Ppap2c T28D9.3 D – – D
Syt11 T23H2.2 D – – D
U, up-regulated; D, down-regulated. *The promoter of these dysregulated genes also contain FOXO binding sites (McElwee et al., 2003). –, Not dysregulated.
This table is based on the simple comparison of four studies performed in either C. elegans (McElwee et al., 2003; Murphy et al., 2003) or mouse NSCs (Lee et al.,
2003; Yu et al., 2008).
in which expression of polyQ-expanded N-terminal huntingtin
in touch receptor neurons induced neuronal dysfunction (lossglu
of response to light touch) in the absence of cell death (Parker
et al., 2001). In these animals, increased sir-2.1/SIRT1 dosage pro-
tects from expanded polyQs, with reduction of axonal dystrophy,
whereas sir-2.1 LOF aggravates expanded polyQ toxicity (Parker
et al., 2005). This neuroprotective effect is not due to unrelated
mutations (i.e., mutations producing a Dyf phenotype) in the
high-copy sir-2.1 transgene containing strains as neuroprotection
was observed to the same extent in non-Dyf, sir-2.1 overexpres-
sors (Burnett et al., 2011). Additionally, sir-2.1 neuroprotection in
this model requires daf-16 /FOXO (Parker et al., 2005), empha-
sizing a role for the SIR-2.1/DAF-16 pathway. This suggested
that raising the activity of the SIRT1 pathway may protect from
mutant huntingtin in mammalian models of HD. This notion
was supported by other C. elegans-based studies (Bates et al.,
2006), and consistent with the protective effects of situins in
common neurological disorders. However, studies in Drosophila
melanogaster suggested that Sir-2 knockdown protects from neu-
rodegeneration as induced by N-terminal htt expression in the
compound eye, with no effect of overexpressing Sir-2 (Pallos
et al., 2008). These results suggested that the role of Sir-2 in
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FIGURE 1 | Simplified view of the FOXO network.This diagram shows
signaling pathways well-established (straight arrows) or hypothesized
(dashed arrow) to converge onto FOXO. The list of target gene classes and
physiological outputs is not exhaustive.
mutant polyglutamine neurons may be complex. Nematodes with
expanded polyQ expression in touch receptor neurons recapit-
ulate neuron dysfunction before cell death and pointed to the
FOXO-dependent effect of homozygous loss of Sir-2 (Parker et al.,
2005). Flies with expanded polyQ expression in the eye show neu-
rodegeneration and pointed to an effect of heterozygous loss of
Sir-2 that may be unrelated to longevity (Pallos et al., 2008).
While these differences illustrated the importance of parame-
ters such as the severity of pathology, type of gene dosage and
identity of downstream effectors when pursuing therapeutic tar-
gets, two independent studies recently reported that SIRT1 is
neuroprotective in several mouse models of HD (Jeong et al.,
2011;Jiang et al., 2011). Interestingly, FOXO3a may be involved
in the neuroprotective effects of SIRT1 and the reduction of
SIRT1 exacerbates mutant huntingtin toxicity (Jiang et al., 2011),
which should help settle the question. Besides SIRT1 manipu-
lation, SIRT2 inhibition may also be neuroprotective in diseases
such as HD (Luthi-Carter et al., 2010) and PD (Outeiro et al.,
2007). As suggested by the function of SIRT2, a microtubule
deacetylase, and by the effects of SIRT2 inhibitors in models of
HD (Luthi-Carter et al., 2010), the mechanisms for neuropro-
tection by SIRT2 inhibition may differ from those elicited by
SIRT1 manipulation. However, FOXO proteins are deacetylated
by SIRT2 (Zhao et al., 2010; Wang et al., 2011), raising the pos-
sibility that neuroprotection by SIRT2 inhibition might involve
FOXO activity.
Consistent with the protection of mutant polyQ neurons by
SIR-2/SIRT1, neuroprotection by sir-2.1 overexpression was also
demonstrated in C. elegans nematodes expressing octa-repeat
expanded PrP in mechanosensory neurons (Bizat et al., 2010).
In these animals, the neuroprotective effect of sir-2.1 was unre-
lated to an effect on the conformation of mutant PrP since sir-2.1
overexpression did not reduce proteinase K-resistant PrP levels
(Bizat et al., 2010). Several studies have further extended the neu-
roprotective activity of SIR-2/SIRT1 and FOXO in models of neu-
rodegenerative diseases. Sirtuin SIRT1 is up-regulated in mouse
models of AD and amyotrophic lateral sclerosis (ALS), and SIRT1
is protective in cell-based models of ALS and AD/tauopathies
(Kim et al., 2007), providing evidence for SIRT1 to protect dis-
eased neurons. Neurite outgrowth, cell viability and tolerance to
degeneration induced by Aβ(1–42) oligomers are promoted in
primary neurons from mice with neuron-speciﬁc SIRT1 overex-
pression (Guo et al., 2011), further supporting the notion that
SIRT1 is able to protect diseased neurons. In C. elegans nema-
todes expressing Aβ(1–42) in body wall muscle cells (Link et al.,
2003), daf-16 /FOXO and heat shock factor 1 (hsf-1) cooperate
to regulate a two-step cell survival response involving disaggre-
gation/aggregation (Cohen et al., 2006). Consistently, in a mouse
model of AD (APPswe/Presenilin1-ΔE9 mice), genetically reduc-
ing IGF signaling protects fromAlzheimer’s-like disease symptoms
(Cohen et al., 2009). Finally, it is notable that allelic variation in
FOXO3A was associated with the ability to be long-lived as sug-
gested by several association studies in populations of centenarians
(Willcox et al., 2008; Anselmi et al., 2009; Flachsbart et al., 2009;
Li et al., 2009; Soerensen et al., 2010; Kleindorp et al., 2011).
While the SIR-2.1/DAF-16 pathway may protect mutant polyQ
neurons, it has opposite effects in a C. elegans model of ocu-
lopharyngeal muscular dystrophy (OPMD), a late-onset disease
caused by expanded polyalanines in the PABPN1 protein (Catoire
et al., 2008). In C. elegans transgenics expressing human PABPN1
in body wall muscle cells, sir-2.1 overexpression indeed aggra-
vates muscle cell decline and abnormal motility caused by mutant
PABPN1 expression, whereas sir-2.1 LOF is protective in a daf-
16 /FOXO-dependent manner (Catoire et al., 2008). These obser-
vations suggested that the status of FOXOactivity inmutant polyQ
neurons is different from that of mutant polyAla muscle cells.
These results also suggested that SIRT1 inhibitors have therapeu-
tic potential in OPMD as further illustrated by pharmacological
studies in PABPN1 nematodes (Pasco et al., 2010).
MODULATION OF NEURODEGENERATIVE DISEASE TARGETS
IN THE FOXO NETWORK
Over the past years, studies of SIRT1/FOXO activity in models
of disease have the search for SIRT1 activators and inhibitors
with clinical potential. While the aim of this review is not to
cover drug discovery and clinical development in the ﬁeld of
sirtuin research, it is notable that the mechanisms of action of
SIRT1-activating compounds (STACs) have been the subject of
debate. This applies to resveratrol, a plant polyphenol that has a
broad range of beneﬁcial activities on health span (Wood et al.,
2004; Baur et al., 2006; Fulda and Debatin, 2006; Lagouge et al.,
2006), is neuroprotective in several models of neurodegenera-
tive diseases (Parker et al., 2005; Kim et al., 2007; Bizat et al.,
2010; Richard et al., 2011) and has attracted a lot of attention
as a potential drug (Patel et al., 2011). Resveratrol was initially
thought to primarily activate SIRT1 (Howitz et al., 2003). It is
now thought that resveratrol has multiple mechanisms of action
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(Harikumar and Aggarwal, 2008). Resveratrol might not always
require SIRT1 for activity against expanded polyQs (Parker et al.,
2005; Pallos et al., 2008), and it could activate AMPK (Dasgupta
and Milbrandt, 2007) and the peroxisome proliferator-activated
receptor coactivator-1alpha (PGC-1alpha; Lagouge et al., 2006)
and inhibits PI3K (Frojdo et al., 2007). This promoted the search
for selective SIRT1 activators (Milne et al., 2007), which led to
ﬁnd that they may act as caloric restriction mimetics (Smith et al.,
2009). Although STACs hold promises for the treatment of age-
associated diseases, their mechanisms of action and therapeutic
potential was controversial. A positive aspect of this controversy
was to emphasize the need for more robust acetylation assays and
in-depth assessment of the promiscuity of STACs. Studies in the
ﬁeld indeed raised the possibility that complex formation between
STACs and ﬂuorophore-labeled substrate peptides plays a role in
the activation of SIRT1 (Pacholec et al., 2010), whereas other stud-
ies subsequently showed that STACs are able to activate unlabelled
peptides, suggesting that STACs may interact directly with SIRT1
and activate SIRT1-catalyzed deacetylation through an allosteric
mechanism (Dai et al., 2010). While the debate regarding STAC
activities might continue, progress appears to be made with har-
nessing the therapeutical potential of STACs inmetabolic disorder.
The development of SRT501 (a formulation of resveratrol) for
diabetes was terminated whereas new STACs structurally distinct
from resveratrol such as SRT2104 are being evaluated (Huber and
Superti-Furga, 2011). Further developments are highly awaited to
know if these molecules may provide clinically safe drugs for neu-
rodegenerative disease. The situation has been less controversial
in regard to sirtuin inhibition as SIRT inhibitors with good selec-
tivity for either SIRT1 (e.g., EX-527) or SIRT2 (e.g., AGK2) have
been identiﬁed (Mai et al., 2009; Luthi-Carter et al., 2010; Pasco
et al., 2010; Taylor et al., 2011). Compared to the mechanisms
for neuroprotection by SIRT1 activation, the biology of neuro-
protection by SIRT inhibition is not understood to that extent.
In any case, progress with identifying the neuronal function of
sirtuins (Dietrich et al., 2010; Ramadori et al., 2010, 2011; Guo
et al., 2011; Maxwell et al., 2011) and targets modulated by these
enzymes (Wang et al., 2007, 2011; Li et al., 2008; Zhao et al., 2010)
will help deﬁne the therapeutic potential of SIRT inhibitors in
neurodegenerative disease.
Besides sirtuins, another neurodegenerative disease target of
interest in the FOXO network is AMPK, a key regulator of cellular
metabolism that is activated by a decrease in energy levels (Stein-
berg and Kemp, 2009). Interestingly, an AMPK–FOXO3a pathway
might be involved in shifting the cell from energy consumption
to energy production in cancer-speciﬁc metabolism (Chiacchiera
and Simone, 2009, 2010; Chiacchiera et al., 2009), a mechanism
also emphasized by the ability of an AMPK–FOXO pathway to
mediate longevity in response to dietary restriction in C. elegans
(Greer et al., 2007). Since there is multiple evidence for mitochon-
drial and metabolic defects in neurodegenerative diseases such
as HD (Zuccato et al., 2010), it is tempting to speculate that
one important mechanism to compensate for metabolic defect
in HD could be the use of an AMPK–FOXO pathway. If true,
then AMPK activation might protect against the early phases of
the pathogenic process in neurodegenerative disease. However,
the AMPK–FOXO pathway may end up activating autophagic cell
death uponprolongedmetabolic stress in cancer cells (Chiacchiera
and Simone,2009,2010;Chiacchiera et al., 2009), raising the possi-
bility that AMPK–FOXO might contribute to neurodegeneration,
which might be particularly harmful during the late phases of
the pathogenic process in neurodegenerative disease. Studies in
models of neurodegeneration reﬂect the complexity of theAMPK-
mediated regulation of cell survival. Although theAMPK activator
metformin protects primary cortical neurons from etoposide-
induced cell death (El-Mir et al., 2008) and ameliorates survival
and motor defects in R6/2 transgenic mice expressing mutant N-
terminal huntingtin (Ma et al., 2007), other studies suggested that
metformin may increase the generation of Aβ peptides via BACE1
upregulation in cellular models (Chen et al., 2009). In regard to
AMPK activity in neurons, conﬂicting observations have been
made. Because neurons do not efﬁciently store nutrients, AMPK
may be essential to neuron activity and survival, suggesting that
AMPK activation might protect neurons from metabolic stress in
neurodegenerative disease. However, AMPK appears to be abnor-
mally activated in pre-tangle and tangle neurons in AD and other
tauopathies (Vingtdeux et al., 2011). Additionally, there is nuclear
translocation of theAMPK-alpha1 subunit in the striatumof post-
mortemHDbrains andmicewith a fast-developingHDpathology
(Ju et al., 2011).While this suggests thatAMPKmight have apatho-
logical role in HD, studies of AMPK in additional models of HD
are warranted considering the pro-survival role of AMPK in neu-
rons and diversity of pathology in HD mice. Collectively, these
data highlight the need for more studies of the modulation of
AMPK activity toward speciﬁc targets in models that recapitulate
the early/mild versus late/severe components of the pathogenic
process in neurodegenerative disease. This will allow the potential
of AMPK-targeted therapy in neurodegenerative disease treatment
to be clariﬁed. It will also be important to identify the small com-
pound molecules that might be used in this respect (Steinberg and
Kemp, 2009).
PERSPECTIVES
There is accumulating evidence on the protective role of FOXO
proteins and their interactors in response to cellular stress in age-
related diseases. One of the current challenges is to identify the
downstream mechanisms by which FOXO factors are essential
to neuron survival in neurodegenerative disease. Given the com-
plex regulation of gene expression by FOXO proteins and their
interactors, it will be important to investigate how FOXO tran-
scriptional targets may be involved in the regulation of survival
responses in speciﬁc neurodegenerative diseases and to evaluate
whether this may be relevant to other neurodegenerative diseases.
Another challenge is to assess whether the pathways that regulate
FOXO transcriptional activity should be activated or inhibited to
modify the pathogenic process in neurodegenerative disease, and
whether the same approach should be used against the early/mild
versus late/severe phases of the pathology. Sustaining neuron sur-
vival at an early phase of the pathology and reducing neuronal cell
death in late disease might require the same FOXO activity to be
modulated in opposing fashions. This possibility is supported by
the ability of FOXO proteins and their interactors to orchestrate
two-step responses in which the net outcome may be cell sur-
vival (Cohen et al., 2006) or cell demise (Chiacchiera and Simone,
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2010) in response to prolonged stress. Thus, while several ques-
tions remain unanswered, future and exciting developments are
expected to shed light on the importance and therapeutic potential
of the FOXO network in neurodegenerative disease.
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